Regional Health is involved in heart failure research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website.
PARAGON: Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF).
PURPOSE: The purpose of this study is to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure (HF) hospitalizations in patients with HF with preserved ejection fraction.
|To learn more, contact:
4150 5th Street
Rapid City, SD
Kelly Airey, MD, FACC, FHRS